LKFT (LKFT) Stock Price & Analysis
LKFT (LKFT) fell 1.00% to USD 27.84 as of July 25, 2026 at 03:51 UTC, according to Nexqual real-time market data.
LKFT last closed at USD 28.12; the session ranged USD 27.78–28.37 on volume of 165,715 shares. Market capitalization is $1.82B, with a 52-week range of USD 26.42–37.78 (NMS). Source: Nexqual, July 25, 2026 at 03:51 UTC.
Key Statistics (as of July 25, 2026 at 03:51 UTC)
| Price | USD 27.84 |
|---|---|
| Change | ▼ 1.00% (down) |
| Previous Close | USD 28.12 |
| Open | USD 28.19 |
| Day Range | USD 27.78 – 28.37 |
| 52-Week Range | USD 26.42 – 37.78 |
| Volume | 165,715 shares |
| Market Cap | $1.82B |
| Exchange | NMS |
Technical Analysis (LKFT)
Nexqual's technical model rates LKFT "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:51 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.21 (neutral) |
| vs SMA50 | Below (USD 28.68) |
| MACD | -0.12 (negative) |
Analyst Ratings (LKFT)
Wall Street analysts rate LKFT "Hold" based on 3 analysts, with a mean price target of USD 25.18 (range USD 18.6–29.85), per Nexqual as of July 25, 2026 at 03:51 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 25.18 |
| High Target | USD 29.85 |
| Low Target | USD 18.6 |
| Buy / Hold / Sell | 0 / 4 / 1 |
Earnings (LKFT)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -11.5 |
| Revenue Estimate | $6.13M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.21 vs est -0.97 ▲ beat |
| 2025-12-31 | USD 12.27 vs est -0.07 ▲ beat |
| 2025-09-30 | USD -0.18 vs est -0.28 ▲ beat |
| 2025-06-30 | USD -0.93 vs est -0.13 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Financials & Fundamentals (LKFT)
| Total Revenue | $1.04B |
|---|---|
| Revenue Growth (YoY) | -91.40% |
| Gross Margin | +68.53% |
| Operating Margin | -982.92% |
| Profit Margin | +46.83% |
| ROE | +16.26% |
| Debt / Equity | 0.2 |
| Current Ratio | 30.48 |
| Total Cash | $2.98B |
| Total Debt | $6.43M |
| Free Cash Flow | $210.97M |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Financial Health Score (LKFT)
Nexqual rates LKFT's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 03:51 UTC.
| Growth | Strong — Revenue +303% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $2.98B cash vs $6M debt, net cash position |
| Cash Flow | Strong — FCF $211M, 19% margin |
| Efficiency | Solid — ROE 16%, ROA 10.7% |
Ownership (LKFT)
| Insider Ownership | +25.35% |
|---|---|
| Institutional Ownership | +22.59% |
| Shares Outstanding | 65.48M |
| Float | 818.81M |
| Short % of Float | +5.56% |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Leadership (LKFT)
LKFT is led by Henry Gosebruch, CEO & Executive Director, per Nexqual as of July 25, 2026 at 03:51 UTC.
| CEO & Executive Director | Henry Gosebruch |
|---|---|
| Chief Financial Officer | Aaron L. Cox (age 41) |
Major Backers & Investors (LKFT)
Notable institutional backers of LKFT include Gilead Sciences Inc, Tang Capital Management, LLC, Madison Avenue Partners, LP, according to Nexqual as of July 25, 2026 at 03:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Gilead Sciences Inc | 25.35% |
| Tang Capital Management, LLC | 5.75% |
| Madison Avenue Partners, LP | 3.74% |
| EcoR1 Capital, LLC | 2.53% |
| Prosight Management, Lp | 2.35% |
| Ameriprise Financial, Inc. | 2.16% |
| Segall Bryant & Hamill, LLC | 0.79% |
| DME Capital Management, LP | 0.73% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Columbia Threadneedle | 1.82% |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARGX | argenx SE | USD 918.22 | ▲ 7.81% |
| RARE | Ultragenyx Pharmaceutical Inc. | USD 26.9 | ▼ 2.69% |
| XNCR | Xencor, Inc. | USD 19.44 | ▼ 0.36% |
| ASND | Ascendis Pharma A/S | USD 253.86 | ▲ 0.77% |
| KYNB | Kyntra Bio, Inc. | USD 7.03 | ▼ 2.56% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:51 UTC. This page is informational and not investment advice.